Meet Katharine | Pradaxa® Patient Profiles | Boehringer Ingelheim

Meet Katharine

  • 69 years old
  • Enjoys tai chi with her friends
  • Taking warfarin for nonvalvular atrial
    fibrillation (NVAF) but is tired of lab visits
    and needles

How will you counsel
Katharine on alternatives to
warfarin?

Scroll to
find out

Katharine will thank you for switching
her to Pradaxa®

‘Pradaxa offers patients superior safety and the ability to reverse effects with Praxbind® in the event of an emergency’
With Pradaxa®, you can also offer Katharine the reassurance of immediate
reversibility with Praxbind® in the event of an emergency.

Not head-to-head studies; real-world, observational analyses.
In the EU, the licensed doses for Pradaxa® are 150 mg BID and 110 mg BID for the prevention of stroke and systemic embolism in adult patients with NVAF.
In the United States, the licensed doses for Pradaxa® are 150 mg BID and 75 mg BID for the prevention of stroke and systemic embolism in adult patients with NVAF.

How to switch Katharine from warfarin
to Pradaxa®

‘There is a three-step process when changing from Warfarin to Pradaxa’

Life Happens

If Katharine ever needs it, Praxbind® provides the reassurance of specific, immediate, and complete reversal of Pradaxa®

  • Dual indication—for life-threatening or uncontrolled bleeding and emergency surgery/urgent procedures6

  • Specific binding allows for immediate and complete reversal of Pradaxa® with no procoagulant effects6

  • Easy to use—1 ready-to-use dose for ALL Pradaxa® patients6

  • Widely available—8,300+ sites in 48 countries7

  • References:
  • 1. Graham DJ et al. Circulation. 2015;131(2):157-164.
  • 2. Larsen TB et al. BMJ. 2016;353:i3189.
  • 3. Villines TC et al. Thromb Haemost. 2015;114(6):1290-1298.
  • 4. Lin I et al. Poster presented at: European Society of Cardiology Congress; August 29-September 2, 2015; London, UK.
  • 5. Pradaxa® (dabigatran etexilate) Summary of Product Characteristics. 2017.
  • 6. Praxbind® (idarucizumab) Summary of Product Characteristics. 2018.
  • 7. Data on file. Boehringer Ingelheim.